Pfizer Inc. (PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.
Read moreThis week’s highlights include two major medical conferences, the ERS International Congress 2014 and MSBoston2014. Many large names in the pharmaceutical and biotech sector, such as GlaxoSmithKline plc(GSK), Biogen Idec Inc (BIIB), and Abbvie Inc. (ABBV) will present on the experimental drugs in their pipelines and their current development.
Read morePrime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.
Read moreSigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets.
Read moreThe Global Maleic Anhydride Industry Report 2014 is a professional and in-depth study on the current state of the global maleic anhydride industry.
Read moreResearch and Markets has announced the addition of the "Polyisobutylene? (Butyl Rubber) Market for Automotives, Additives and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" report to their offering.
Read more"Epoxy Resin market by Application (Coatings, Electronics, Construction, Wind Turbine, Composites, and Adhesives) and Geography - Trends & Forecast to 2019" by MarketsandMarkets, the market of epoxy resin is projected to grow from an estimated $5,995.8 million in 2013 to $9,219.1 million by 2019, with a CAGR of 7.4% between 2014 and 2019.
Read moreAllergan ($AGN), working to fend off a hostile approach from Valeant Pharmaceuticals ($VRX), is reportedly taking a look at the smaller Salix Pharmaceuticals ($SLXP), weighing a multibillion-dollar deal that could render it unattainable--or at least drive up its asking price.
Read more
2010-2021 © Chemical Cloud Database. ALL Rights Reserved.浙ICP备11020424号-1
浙公网安备 33010802004002号